Pro‐gastrin–releasing peptide as a factor predicting the incidence of brain metastasis in patients with small cell lung carcinoma with limited disease receiving prophylactic cranial irradiation

Prophylactic cranial irradiation (PCI) reduces the incidence of brain metastasis with an effect on overall survival in patients with small cell lung carcinoma (SCLC). In spite of multidisciplinary intensive treatment approaches, many patients still experience brain metastasis. The authors retrospectively analyzed the characteristics of the first failure event due to brain metastasis (FBM) in patients treated with PCI.

[1]  J. Mackay,et al.  Practice guideline for the role of combination chemotherapy in the initial management of limited-stage small-cell lung cancer. , 2004, Lung cancer.

[2]  Charles R. Thomas,et al.  Ten-year follow-up of Southwest Oncology Group 8269: a phase II trial of concomitant cisplatin-etoposide and daily thoracic radiotherapy in limited small-cell lung cancer. , 2001, Lung cancer.

[3]  E. Yu,et al.  Practice guideline on prophylactic cranial irradiation in small-cell lung cancer. , 2001, International journal of radiation oncology, biology, physics.

[4]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[5]  P. Harper,et al.  Predictive and prognostic factors in small cell lung cancer: current status. , 2000, Lung cancer.

[6]  J P Pignon,et al.  Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. , 1999, The New England journal of medicine.

[7]  N. Sunaga,et al.  Serum Pro-Gastrin-Releasing Peptide Is a Useful Marker for Treatment Monitoring and Survival in Small-Cell Lung Cancer , 1999, Oncology.

[8]  R. Komaki,et al.  Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. , 1999, The New England journal of medicine.

[9]  D. Girling,et al.  Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: Results of a multicentre randomised trial , 1997 .

[10]  M. Fukuoka,et al.  Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase. , 1996, British Journal of Cancer.

[11]  N. Maki,et al.  Enzyme‐linked Immunosorbent Assay of Pro‐gastrin‐releasing Peptide for Small Cell Lung Cancer Patients in Comparison with Neuron‐specific Enolase Measurement , 1995, Japanese journal of cancer research : Gann.

[12]  P Chomy,et al.  Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. , 1995, Journal of the National Cancer Institute.

[13]  R. Arriagada,et al.  Competing events determining relapse-free survival in limited small-cell lung carcinoma. The French Cancer Centers' Lung Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  H. Sugano,et al.  A Statistical Analysis of Lung Cancer Registered in the Annual of Pathological Autopsy Cases in Japan between 1958 and 1987, with Special Reference to the Characteristics of Lung Cancer in Japan , 1990, Acta pathologica japonica.

[15]  J. Crowley,et al.  Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  G. Kalemkerian,et al.  Small cell lung cancer , 2010, Seminars in Respiratory and Critical Care Medicine.

[17]  R. Makuch,et al.  Role of prophylactic cranial irradiation in prevention of central nervous system metastases in small cell lung cancer. Potential benefit restricted to patients with complete response. , 1983, The American journal of medicine.

[18]  F. Hirsch,et al.  Intracranial metastases in small cell carcinoma of the lung prognostic aspects , 1983, Cancer.

[19]  J. Cox,et al.  Risk of brain metastasis from small cell carcinoma of the lung related to length of survival and prophylactic irradiation. , 1981, Cancer treatment reports.

[20]  F. Hirsch,et al.  Prophylactic irradiation in bronchogenic small cell anaplastic carcinoma. A comparative trial of localized versus extensive radiotherapy including prophylactic brain irradiation in patients receiving combination chemotherapy , 1980, Cancer.

[21]  H. Hansen,et al.  Frequency, diagnosis, and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma , 1974 .

[22]  Hansen Hh.  Should initial treatment of small cell carcinoma include systemic chemotherapy and brain irradiation , 1973 .

[23]  Cancer Care Ontario Practice Guidelines Initiative , 2003 .

[24]  K. Eguchi,et al.  Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[26]  J. Ingle,et al.  A case for preplanned thoracic and prophylactic whole brain radiation therapy in limited small-cell lung cancer. , 1981, Cancer clinical trials.

[27]  T. Pajak,et al.  A randomized combined modality trial in small cell carcinoma of the lung comparison of combination chemotherapy‐radiation therapy versus cyclophosphamide‐radiation therapy effects of maintenance chemotherapy and prophylactic whole brain irradiation , 1980, Cancer.

[28]  R. Gelber,et al.  The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. , 1980, International journal of radiation oncology, biology, physics.

[29]  H. Hansen.  Should initial treatment of small cell carcinoma include systemic chemotherapy and brain irradiation? , 1973, Cancer chemotherapy reports. Part 3.

[30]  M. Uslenghi,et al.  The World Space Observatory (WSO-UV) - Current status , 2008, 0801.2080.